GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kobayashi Pharmaceutical Co 4967.T · JPY

Consumer Staples · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

7,001

+0.14%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥165.74bn

FY2016FY2025

Net income

¥3.66bn

FY2016FY2025

Free cash flow

¥12.34bn

FY2016FY2025

Shareholders' equity

¥211.00bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥165.74bn¥165.60bn¥173.46bn¥166.26bn¥155.25bn¥150.51bn¥168.05bn¥167.48bn¥156.76bn¥152.65bn
Gross profit¥84.71bn¥87.60bn¥96.38bn¥92.33bn¥88.77bn¥85.27bn¥103.35bn¥103.12bn¥95.52bn¥89.85bn
Research and development¥9.12bn¥9.11bn¥9.00bn¥8.33bn¥7.52bn¥7.34bn¥7.11bn¥7.03bn¥7.24bn¥9.91bn
Operating income¥14.92bn¥24.86bn¥25.78bn¥26.67bn¥26.07bn¥25.94bn¥26.36bn¥26.29bn¥22.93bn¥18.99bn
Net income¥3.66bn¥10.07bn¥20.34bn¥20.02bn¥19.71bn¥19.20bn¥19.14bn¥18.02bn¥15.86bn¥15.33bn
Diluted earnings per share49.18135.42271.06261.26252.35245.70244.86228.29200.89190.86

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥275.33bn¥265.37bn¥267.47bn¥255.83bn¥252.55bn¥238.37bn¥233.73bn¥228.79bn¥218.83bn¥201.23bn
Cash and short-term investments¥70.61bn¥65.75bn¥79.84bn¥104.53bn¥109.05bn¥94.34bn¥90.56bn¥82.76bn¥73.29bn¥63.67bn
Total liabilities¥64.32bn¥51.89bn¥62.66bn¥57.93bn¥56.95bn¥55.78bn¥61.07bn¥62.54bn¥65.02bn¥57.91bn
Debt¥678.0m¥846.0m¥987.0m¥792.0m¥630.0m¥688.0m¥891.0m¥1.03bn¥1.25bn¥1.29bn
Shareholders' equity¥211.00bn¥213.47bn¥204.82bn¥197.90bn¥195.60bn¥182.58bn¥172.66bn¥166.25bn¥153.81bn¥143.32bn
Shares outstanding74m74m75m77m78m78m78m79m79m80m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations¥25.59bn¥11.25bn¥18.36bn¥31.91bn¥22.42bn¥23.99bn¥20.09bn¥20.01bn¥22.35bn¥16.10bn
Capital spending−¥13.25bn−¥26.06bn−¥12.76bn−¥14.75bn−¥3.66bn−¥3.79bn−¥4.38bn−¥3.42bn−¥2.84bn−¥2.85bn
Free cash flow¥12.34bn−¥14.81bn¥5.60bn¥17.17bn¥18.76bn¥20.19bn¥15.71bn¥16.59bn¥19.51bn¥13.25bn
Dividends paid−¥7.65bn−¥7.50bn−¥7.22bn−¥6.51bn−¥6.25bn−¥5.78bn−¥5.33bn−¥4.82bn−¥4.34bn−¥3.92bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥37.08bn¥33.66bn¥53.70bn¥43.02bn¥36.41bn¥32.61bn¥51.14bn¥41.32bn
Gross profit¥18.52bn¥17.07bn¥25.85bn¥22.72bn¥19.46bn¥16.68bn¥24.91bn¥21.94bn
Operating income¥811.0m¥1.35bn¥3.43bn¥4.85bn¥4.11bn¥2.54bn¥7.88bn¥7.50bn
Net income¥101.0m¥1.04bn−¥3.15bn¥3.64bn¥1.54bn¥1.62bn¥4.72bn¥3.91bn
Diluted earnings per share1.3613.94-42.4148.9920.7621.8563.5352.57
Cash from operations¥230.0m———————
Capital spending−¥5.07bn———————
Free cash flow−¥4.84bn———————
Total assets¥251.89bn¥254.86bn¥275.33bn¥261.45bn¥260.71bn¥251.75bn¥265.37bn¥250.48bn
Cash and short-term investments¥57.33bn¥65.03bn¥70.61bn¥57.97bn¥69.67bn¥67.28bn¥65.75bn¥51.67bn
Debt¥271.0m¥332.0m¥319.0m¥342.0m¥355.0m¥363.0m¥343.0m¥371.0m
Shareholders' equity¥209.69bn¥208.92bn¥211.00bn¥212.04bn¥208.24bn¥207.06bn¥213.47bn¥204.69bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.1%1.9%1.9%
Operating income-17.6%-10.5%-2.0%
Net income-43.3%-28.2%-12.2%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin52.0%53.8%54.8%57.2%
Operating margin12.0%13.7%14.8%14.6%
Net margin4.1%8.1%9.5%9.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings110.446.025.134.635.851.337.932.736.426.2
Price to sales2.42.82.94.24.56.54.33.53.72.6

Dividends and splits

Per share, in the currency the company pays

Paid for 25 years. Last went ex-dividend on 29 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year45.00163.00101.0095.0084.0080.0074.0068.00
  • 2-for-1 split · 28 Jun 2016
  • 1.5-for-1 split · 25 Sept 2003

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.